<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_APSB809 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEgr4 jpg ?>
<?FILEgr5 jpg ?>
<?FILEgr6 jpg ?>
<?FILEfx1 jpg ?>
<?FILEfx2 jpg ?>
<?FILEfx3 jpg ?>
<?FILEfx4 jpg ?>
<?FILEfx5 jpg ?>
<?FILEfx6 jpg ?>
<?FILEfx7 jpg ?>
<?FILEmmc1 pdf ?>
<?FILEsi1 svg ?>
<?FILEsi2 svg ?>
<?FILEsi3 svg ?>
<?FILEsi4 svg ?>
<?FILEsi5 svg ?>
<?FILEsi6 svg ?>
<?FILEsi7 svg ?>
<?FILEsi8 svg ?>
<?FILEsi9 svg ?>
<?FILEsi10 svg ?>
<?FILEsi11 svg ?>
<?FILEsi12 svg ?>
<?FILEsi13 svg ?>
<?FILEsi14 svg ?>
<?FILEsi15 svg ?>
<?FILEsi16 svg ?>
<?FILEsi17 svg ?>
<?FILEsi18 svg ?>
<?FILEsi19 svg ?>
<?FILEsi20 svg ?>
<?properties open_access?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Acta Pharm Sin B</journal-id>
    <journal-id journal-id-type="iso-abbrev">Acta Pharm Sin B</journal-id>
    <journal-title-group>
      <journal-title>Acta Pharmaceutica Sinica. B</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">2211-3835</issn>
    <issn pub-type="epub">2211-3843</issn>
    <publisher>
      <publisher-name>Elsevier</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7169934</article-id>
    <article-id pub-id-type="publisher-id">S2211-3835(20)30549-9</article-id>
    <article-id pub-id-type="doi">10.1016/j.apsb.2020.04.006</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au1">
        <name>
          <surname>Shi</surname>
          <given-names>Yulong</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="aff2" ref-type="aff">b</xref>
        <xref rid="fn1" ref-type="fn">†</xref>
      </contrib>
      <contrib contrib-type="author" id="au2">
        <name>
          <surname>Zhang</surname>
          <given-names>Xinben</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="fn1" ref-type="fn">†</xref>
      </contrib>
      <contrib contrib-type="author" id="au3">
        <name>
          <surname>Mu</surname>
          <given-names>Kaijie</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="aff3" ref-type="aff">c</xref>
        <xref rid="fn1" ref-type="fn">†</xref>
      </contrib>
      <contrib contrib-type="author" id="au4">
        <name>
          <surname>Peng</surname>
          <given-names>Cheng</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="aff2" ref-type="aff">b</xref>
        <xref rid="fn1" ref-type="fn">†</xref>
      </contrib>
      <contrib contrib-type="author" id="au5">
        <name>
          <surname>Zhu</surname>
          <given-names>Zhengdan</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="aff2" ref-type="aff">b</xref>
      </contrib>
      <contrib contrib-type="author" id="au6">
        <name>
          <surname>Wang</surname>
          <given-names>Xiaoyu</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au7">
        <name>
          <surname>Yang</surname>
          <given-names>Yanqing</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="aff2" ref-type="aff">b</xref>
      </contrib>
      <contrib contrib-type="author" id="au8">
        <name>
          <surname>Xu</surname>
          <given-names>Zhijian</given-names>
        </name>
        <email>zjxu@simm.ac.cn</email>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="aff2" ref-type="aff">b</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <contrib contrib-type="author" id="au9">
        <name>
          <surname>Zhu</surname>
          <given-names>Weiliang</given-names>
        </name>
        <email>wlzhu@simm.ac.cn</email>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="aff2" ref-type="aff">b</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <aff id="aff1"><label>a</label>CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</aff>
      <aff id="aff2"><label>b</label>School of Pharmacy, University of Chinese Academy of Sciences, Beijing 100049, China</aff>
      <aff id="aff3"><label>c</label>Nano Science and Technology Institute, University of Science and Technology of China, Suzhou 215123, China</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>∗</label>Corresponding authors. Tel.: +86 21 50806600 1201 (Zhijian Xu), +86 21 50805020 (Weiliang Zhu). <email>zjxu@simm.ac.cn</email><email>wlzhu@simm.ac.cn</email></corresp>
      <fn id="fn1">
        <label>†</label>
        <p id="ntpara0015">These authors made equal contributions to this work.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>20</day>
      <month>4</month>
      <year>2020</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="ppub">
      <month>7</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>20</day>
      <month>4</month>
      <year>2020</year>
    </pub-date>
    <volume>10</volume>
    <issue>7</issue>
    <fpage>1239</fpage>
    <lpage>1248</lpage>
    <history>
      <date date-type="received">
        <day>1</day>
        <month>3</month>
        <year>2020</year>
      </date>
      <date date-type="rev-recd">
        <day>23</day>
        <month>3</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>25</day>
        <month>3</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.</copyright-statement>
      <copyright-year>2020</copyright-year>
      <copyright-holder>Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences</copyright-holder>
      <license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="abs0010">
      <title>Abstract</title>
      <p>A highly effective medicine is urgently required to cure coronavirus disease 2019 (COVID-19). For the purpose, we developed a molecular docking based webserver, namely D3Targets-2019-nCoV, with two functions, one is for predicting drug targets for drugs or active compounds observed from clinic or <italic>in vitro</italic>/<italic>in vivo</italic> studies, the other is for identifying lead compounds against potential drug targets <italic>via</italic> docking. This server has its unique features, (1) the potential target proteins and their different conformations involving in the whole process from virus infection to replication and release were included as many as possible; (2) all the potential ligand-binding sites with volume larger than 200 Å<sup>3</sup> on a protein structure were identified for docking; (3) correlation information among some conformations or binding sites was annotated; (4) it is easy to be updated, and is accessible freely to public (https://www.d3pharma.com/D3Targets-2019-nCoV/index.php). Currently, the webserver contains 42 proteins [20 severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) encoded proteins and 22 human proteins involved in virus infection, replication and release] with 69 different conformations/structures and 557 potential ligand-binding pockets in total. With 6 examples, we demonstrated that the webserver should be useful to medicinal chemists, pharmacologists and clinicians for efficiently discovering or developing effective drugs against the SARS-CoV-2 to cure COVID-19.</p>
    </abstract>
    <abstract abstract-type="graphical" id="abs0015">
      <title>Graphical abstract</title>
      <p>D3Targets-2019-nCoV is a webserver built for the purpose to find effective medicines against the SARS-CoV-2 to cure COVID-19, with two functions, one is for predicting target proteins for drugs or active compounds, and the other is for identifying lead compounds against potential drug targets <italic>via</italic> docking.<fig id="undfig1" position="anchor"><alt-text id="alttext0010">Image 1</alt-text><graphic xlink:href="fx1"/></fig></p>
    </abstract>
    <kwd-group id="kwrds0010">
      <title>KEY WORDS</title>
      <kwd>COVID-19</kwd>
      <kwd>SARS-CoV-2</kwd>
      <kwd>Target prediction</kwd>
      <kwd>Multi-conformation</kwd>
      <kwd>Multi-site</kwd>
      <kwd>Docking</kwd>
      <kwd>D3Targets-2019-nCoV</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <label>1</label>
    <title>Introduction</title>
    <p id="p0015">Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2)<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> has caused more than 2800 deaths as of 29 February 2020 worldwide. Drug researchers and clinicians are working intensively hard to discover and test drugs against the coronavirus disease 2019 (COVID-19). For example, intravenous treatment of remdesivir has been reported to be helpful to improve the clinical condition for the first confirmed patient of SARS-CoV-2 infection in the United States, although the safety and efficacy are still needed to test in randomized controlled trials<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref>. Nevertheless, there are many incoming or ongoing clinical studies in China, but no drug has been approved to be effective for COVID-19 so far.</p>
    <p id="p0020">In order to discover effective drugs against the virus, virtual screening studies have been performed based on several proteins, including 3C-like proteinase (M<sup>pro</sup>)<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, angiotensin converting enzyme 2 (ACE2)<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref>, papain-like proteinase (PLpro)<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref>, and furin<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref>. However, the clinic study did not discover desirable medicine. Therefore, more potential drug targets should be explored for virtual screening and drug design. As the whole process of viral disease involves not only the proteins encoded by the SARS-CoV-2 itself, but also the proteins of human being. Thus, both the viral protein and human protein should be included for drug discovery and development, and the virtual screening against more potential target proteins could reduce false negative and improve the success rate to quickly find cures for the disease. Moreover, multi-site docking is also indispensable for deep exploration of protein functions and drug discovery. On one hand, the functional sites of some proteins are unclear or not unique, which should be comprehensively considered. On the other hand, there may be allosteric sites on the protein, which may have distinct advantages for regulating protein function. In conclusion, multi-target and multi-site based virtual screening is a more expected and comprehensive approach for finding targeted therapeutic drugs, which can improve the accuracy and robustness of prediction as much as possible.</p>
    <p id="p0025">There are at least 126 planning or ongoing clinical studies against the SARS-CoV-2 as of 29 February 2020 according to the information from Chinese Clinical Trial Registry as shown in Supporting Information <xref rid="appsec1" ref-type="sec">Table S1</xref>. For example, chloroquine, an anti-plasmodium drug, has been found partially effective in clinic. However, its exact target protein and function mechanism against the virus and COVID-19 are unknown. In addition, many groups are working on the cytopathic effect assay for discovering drugs or active compounds against the SARS-CoV-2. This kind of <italic>in vitro</italic> study may result in compounds with good activity yet unknown targets. Therefore, identifying potential drug targets will be of great importance to understand the underlying mechanism of how the drug works, and to provide information for further drug development. Thus, a platform is expected to provide reverse docking function for predicting target protein for mechanism unknown but active compounds and drugs.</p>
    <p id="p0030">To the best of our knowledge, there is no webserver available to perform virtual screening for discovering drugs based on the multi-target and multi-site strategy and to run reverse docking for predicting potential drug target. Here, we report a platform, namely D3Targets-2019-nCoV webserver, with two functions, one is for predicting drug targets for active compounds or drugs observed from clinic test or <italic>in vitro</italic>/<italic>in vivo</italic> study, and the other is for identifying lead compounds against a specific or multiple drug targets <italic>via</italic> protein structure based virtual screening. We hope this platform could help the medicinal chemists, pharmacologists and clinicians to efficiently discover and develop drugs against the SARS-CoV-2 to cure COVID-19.</p>
  </sec>
  <sec id="sec2">
    <label>2</label>
    <title>Materials and methods</title>
    <sec id="sec2.1">
      <label>2.1</label>
      <title>Potential target proteins included in the D3Targets-2019-nCoV database</title>
      <p id="p0035">In order to find potential target proteins as many as possible for discovering drugs to cure COVID-19, it is necessary to consider both the SARS-CoV-2 proteins and human proteins involved in the whole process of virus infection, replication and release. In total, there are 42 potential proteins included in the database as of 21 March 2020, among which 20 proteins are encoded by the virus itself, and 22 proteins are encoded by human genome (<xref rid="tbl1" ref-type="table">Table 1</xref>).<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Information of the D3Targets-2019-nCoV database.</p></caption><alt-text id="alttext0050">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>No.</th><th>Target full name</th><th>Target abbreviation</th><th>Protein ID/UniProtKB</th><th>State/conformation</th><th>Mark<xref rid="fn2" ref-type="table-fn">a</xref></th><th>Number of pockets<xref rid="fn3" ref-type="table-fn">b</xref></th><th>Orthosteric pockets<xref rid="fn4" ref-type="table-fn">c</xref></th><th>PDB ID</th><th>Sequence similarity (%)</th></tr></thead><tbody><tr><td>1</td><td>Host translation inhibitor nsp 1</td><td>Nsp 1</td><td>QHD43415.1</td><td>/<xref rid="fn5" ref-type="table-fn">d</xref></td><td>V1</td><td>3</td><td>/</td><td>2HSX</td><td>86.09</td></tr><tr><td>2</td><td>Non-structural protein 2</td><td>Nsp 2</td><td>QHD43415.1</td><td>/</td><td>V2</td><td>13</td><td>/</td><td>/</td><td>/</td></tr><tr><td rowspan="2">3</td><td>Papain-like proteinase</td><td>PLP/PLpro</td><td>QHD43415.1</td><td>Monomer</td><td>V3-1</td><td>6</td><td>1</td><td>3E9S</td><td>82.86</td></tr><tr><td/><td/><td/><td>Dimer</td><td>V3-2</td><td>9</td><td>1</td><td>5Y3E</td><td>82.80</td></tr><tr><td rowspan="2">4</td><td>ADP ribose phosphatase</td><td>ADRP</td><td>QHD43415.1</td><td>Monomer</td><td>V4-1*</td><td>1</td><td>1</td><td>6W02</td><td>/</td></tr><tr><td/><td/><td/><td>Dimer</td><td>V4-2*</td><td>5</td><td>2, 3</td><td>6W02</td><td>/</td></tr><tr><td>5</td><td>Non-structural protein 4</td><td>Nsp 4</td><td>QHD43415.1</td><td>/</td><td>V5</td><td>7</td><td>/</td><td>/</td><td>/</td></tr><tr><td rowspan="8">6</td><td>3C-like proteinase</td><td>3CLpro/Mpro</td><td>QHD43415.1</td><td>Monomer</td><td>V6-1</td><td>4</td><td>2</td><td>1Z1I</td><td>96.01</td></tr><tr><td/><td/><td/><td>Monomer</td><td>V6-2*</td><td>7</td><td>1</td><td>5R82</td><td>/</td></tr><tr><td/><td/><td/><td>Dimer</td><td>V6-3</td><td>6</td><td>3, 4</td><td>2Z9J</td><td>96.08</td></tr><tr><td/><td/><td/><td>Dimer</td><td>V6-4*</td><td>7</td><td>3, 4</td><td>6Y2G</td><td>/</td></tr><tr><td/><td/><td/><td>MD1<sup>#</sup></td><td>V6-5</td><td>6</td><td>1</td><td>1Z1I</td><td>96.01</td></tr><tr><td/><td/><td/><td>MD2<sup>#</sup></td><td>V6-6</td><td>6</td><td>2</td><td>1Z1I</td><td>96.01</td></tr><tr><td/><td/><td/><td>MD3<sup>#</sup></td><td>V6-7</td><td>6</td><td>3</td><td>1Z1I</td><td>96.01</td></tr><tr><td/><td/><td/><td>MD4<sup>#</sup></td><td>V6-8</td><td>7</td><td>3</td><td>1Z1I</td><td>96.01</td></tr><tr><td>7</td><td>Non-structural protein 6</td><td>Nsp 6</td><td>QHD43415.1</td><td>/</td><td>V7</td><td>7</td><td>/</td><td>/</td><td>/</td></tr><tr><td>8</td><td>Non-structural protein 7</td><td>Nsp 7</td><td>QHD43415.1</td><td>/</td><td>V8</td><td>1</td><td>/</td><td>1YSY</td><td>98.80</td></tr><tr><td>9</td><td>Non-structural protein 8</td><td>Nsp 8</td><td>QHD43415.1</td><td>/</td><td>V9</td><td>1</td><td>/</td><td>2AHM</td><td>97.42</td></tr><tr><td rowspan="4">10</td><td>Non-structural protein 9</td><td>Nsp 9</td><td>QHD43415.1</td><td>Monomer</td><td>V10-1</td><td>3</td><td>/</td><td>1UW7</td><td>97.35</td></tr><tr><td/><td/><td/><td>Monomer</td><td>V10-2*</td><td>3</td><td>/</td><td>6W4B</td><td>/</td></tr><tr><td/><td/><td/><td>Dimer</td><td>V10-3</td><td>7</td><td>/</td><td>1QZ8</td><td>97.35</td></tr><tr><td/><td/><td/><td>Dimer</td><td>V10-4*</td><td>6</td><td>/</td><td>6W4B</td><td>/</td></tr><tr><td>11</td><td>Non-structural protein 10</td><td>Nsp 10</td><td>QHD43415.1</td><td>/</td><td>V11</td><td>3</td><td>/</td><td>5NFY</td><td>98.47</td></tr><tr><td rowspan="2">12</td><td>RNA-dependent RNA polymerase</td><td>RdRp</td><td>QHD43415.1</td><td>/</td><td>V12-1</td><td>10</td><td>/</td><td>6NUR</td><td>96.35</td></tr><tr><td/><td/><td/><td>+Mg<sup>2+</sup></td><td>V12-2</td><td>10</td><td>/</td><td>6NUR</td><td>96.35</td></tr><tr><td rowspan="2">13</td><td>Helicase</td><td>/</td><td>QHD43415.1</td><td>Monomer</td><td>V13-1</td><td>11</td><td>/</td><td>6JYT</td><td>99.83</td></tr><tr><td/><td/><td/><td>Dimer</td><td>V13-2</td><td>21</td><td>/</td><td>6JYT</td><td>99.83</td></tr><tr><td>14</td><td>Guanine-<italic>N</italic>7 methyltransferase</td><td><italic>N</italic>7 Mtase</td><td>QHD43415.1</td><td>/</td><td>V14</td><td>12</td><td>1</td><td>5NFY</td><td>94.88</td></tr><tr><td rowspan="3">15</td><td>Uridylate-specific endoribonuclease</td><td>NendoU</td><td>QHD43415.1</td><td>Monomer</td><td>V15-1</td><td>7</td><td>/</td><td>2H85</td><td>88.12</td></tr><tr><td/><td/><td/><td>Monomer</td><td>V15-2*</td><td>8</td><td>/</td><td>6W01</td><td>/</td></tr><tr><td/><td/><td/><td>Dimer</td><td>V15-3*</td><td>15</td><td>/</td><td>6W01</td><td>/</td></tr><tr><td>16</td><td>2ʹ-<italic>O</italic>-Methyltransferase</td><td>2ʹ-<italic>O</italic>-Mtase</td><td>QHD43415.1</td><td>/</td><td>V16</td><td>5</td><td>1</td><td>2XYR</td><td>93.49</td></tr><tr><td>17</td><td>ORF7a protein</td><td>/</td><td>QHD43421.1</td><td>/</td><td>V17</td><td>1</td><td>/</td><td>1YO4</td><td>91.57</td></tr><tr><td rowspan="6">18</td><td>Spike protein</td><td>S protein</td><td>QHD43416.1</td><td>Closed</td><td>V18-1</td><td>25</td><td>/</td><td>5X58</td><td>76.48</td></tr><tr><td/><td/><td/><td>Closed</td><td>V18-2*</td><td>30</td><td>/</td><td>6VXX</td><td>/</td></tr><tr><td/><td/><td/><td>Open</td><td>V18-3</td><td>27</td><td>/</td><td>5 × 5B</td><td>76.48</td></tr><tr><td/><td/><td/><td>Open</td><td>V18-4*</td><td>42</td><td>/</td><td>6VYB</td><td>/</td></tr><tr><td/><td/><td/><td>Heptad repeat 1</td><td>V18-5</td><td>12</td><td>/</td><td>5ZVM</td><td>87.50</td></tr><tr><td/><td/><td/><td>S2 subunit</td><td>V18-6*</td><td>4</td><td/><td>6LXT</td><td>/</td></tr><tr><td rowspan="2">19</td><td>Envelope protein</td><td>E protein</td><td>QHD43418.1</td><td>Monomer</td><td>V19-1</td><td>1</td><td>/</td><td>2MM4</td><td>91.38</td></tr><tr><td/><td/><td/><td>Pentamer</td><td>V19-2</td><td>2</td><td>/</td><td>5X29</td><td>91.38</td></tr><tr><td rowspan="4">20</td><td>Nucleocapsid phosphoprotein</td><td>N protein</td><td>QHD43423.2</td><td>C terminal</td><td>V20-1</td><td>1</td><td>/</td><td>2GIB</td><td>96.04</td></tr><tr><td/><td/><td/><td>N terminal monomer</td><td>V20-2</td><td>4</td><td>/</td><td>2OFZ</td><td>92.06</td></tr><tr><td/><td/><td/><td>N terminal monomer</td><td>V20-3*</td><td>3</td><td>/</td><td>6VYO</td><td>/</td></tr><tr><td/><td/><td/><td>N terminal-tetramer</td><td>V20-4*</td><td>16</td><td>/</td><td>6VYO</td><td>/</td></tr><tr><td>21</td><td>Angiotensin converting enzyme 2</td><td>ACE2</td><td>P59594</td><td>/</td><td>H1*</td><td>6</td><td>/</td><td>1R42</td><td>/</td></tr><tr><td>22</td><td>Cathepsin L</td><td>CTSL</td><td>P07711</td><td>/</td><td>H2*</td><td>5</td><td>1</td><td>2XU3</td><td>/</td></tr><tr><td>23</td><td>Transmembrane protease serine 2</td><td>TMPRSS2</td><td>O15393</td><td>/</td><td>H3</td><td>10</td><td>/</td><td>/</td><td>/</td></tr><tr><td>24</td><td>C type lectin domain family four member M</td><td>CLEC4M</td><td>Q9H2X3</td><td>/</td><td>H4*</td><td>2</td><td>/</td><td>1XAR</td><td>/</td></tr><tr><td>25</td><td>AP2-associated protein kinase 1</td><td>AAK1</td><td>Q2M2I8</td><td>/</td><td>H5*</td><td>12</td><td>1, 6</td><td>5TE0</td><td>/</td></tr><tr><td>26</td><td>Cyclophilin A</td><td>CypA</td><td>P62937</td><td>/</td><td>H6*</td><td>3</td><td>1</td><td>4N1M</td><td>/</td></tr><tr><td rowspan="2">27</td><td>Disintegrin and metalloproteinase domain-containing protein 17</td><td>ADAM17</td><td>P78536</td><td>/</td><td>H7-1</td><td>5</td><td>1</td><td>2I47</td><td>99.21</td></tr><tr><td/><td/><td/><td>+Zn<sup>2+</sup></td><td>H7-2</td><td>5</td><td>1</td><td>2I47</td><td>99.21</td></tr><tr><td>28</td><td>Furin</td><td>/</td><td>P09958</td><td>/</td><td>H8*</td><td>8</td><td>1</td><td>5JXG</td><td>/</td></tr><tr><td>29</td><td>Tyrosine-protein kinase ABL2</td><td>ABL2</td><td>P42684</td><td>/</td><td>H9*</td><td>3</td><td>1</td><td>3HMI</td><td>/</td></tr><tr><td>30</td><td>Eukaryotic initiation factor 4A-I</td><td>eIF4A</td><td>P60842</td><td>/</td><td>H10*</td><td>8</td><td>2</td><td>5ZC9</td><td>/</td></tr><tr><td>31</td><td>Dihydroorotate dehydrogenase</td><td>DHODH</td><td>Q02127</td><td>/</td><td>H11*</td><td>6</td><td>1</td><td>3U2O</td><td>/</td></tr><tr><td>32</td><td>Glycogen synthase kinase-3 beta</td><td>GSK3<italic>β</italic></td><td>P49841</td><td>/</td><td>H12*</td><td>13</td><td>1</td><td>1J1B</td><td>/</td></tr><tr><td>33</td><td>Heterogeneous nuclear ribonucleoprotein A1</td><td>HNRNPA1</td><td>P09651</td><td>/</td><td>H13*</td><td>4</td><td>/</td><td>1U1Q</td><td>/</td></tr><tr><td rowspan="2">34</td><td>Calnexin</td><td>/</td><td>P27823</td><td>/</td><td>H14-1</td><td>7</td><td>/</td><td>1JHN</td><td>95.73</td></tr><tr><td/><td/><td/><td>+Ca<sup>2+</sup></td><td>H14-2</td><td>7</td><td>/</td><td>1JHN</td><td>95.73</td></tr><tr><td>35</td><td>Mitogen-activated protein kinase 8</td><td>JNK1</td><td>P45983</td><td>/</td><td>H15</td><td>12</td><td>1</td><td>2G01</td><td>99.44</td></tr><tr><td>36</td><td>Mitogen-activated protein kinase 9</td><td>JNK2</td><td>P45984</td><td>/</td><td>H16</td><td>6</td><td>1</td><td>3NPC</td><td>98.31</td></tr><tr><td>37</td><td>Mitogen-activated protein kinase 10</td><td>JNK3</td><td>P53779</td><td>/</td><td>H17*</td><td>7</td><td>1</td><td>1JNK</td><td>/</td></tr><tr><td>38</td><td>RAC-alpha serine/threonine-protein kinase</td><td>AKT1</td><td>P31749</td><td>/</td><td>H18*</td><td>8</td><td>1</td><td>3O96</td><td>/</td></tr><tr><td>39</td><td>RAC-beta serine/threonine-protein kinase</td><td>AKT2</td><td>P31751</td><td>/</td><td>H19*</td><td>12</td><td>1</td><td>3D0E</td><td>/</td></tr><tr><td>40</td><td>RAC-gamma serine/threonine-protein kinase</td><td>AKT3</td><td>Q9Y243</td><td>/</td><td>H20*</td><td>5</td><td>/</td><td>2X18</td><td>/</td></tr><tr><td>41</td><td>Caveolin-2</td><td>CAV2</td><td>P51636</td><td>/</td><td>H21</td><td>2</td><td>/</td><td>/</td><td>/</td></tr><tr><td>42</td><td>cGMP-specific 3ʹ,5ʹ-cyclic phosphodiesterase</td><td>PDE5</td><td>O76074</td><td>/</td><td>H22*</td><td>10</td><td>1</td><td>2H44</td><td>/</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>*Crystal structures of SARS-CoV-2 or human proteins downloaded from PDB.</p></fn><fn id="tspara0020"><p><sup>#</sup>Conformations clustered from molecular dynamics trajectories.</p></fn></table-wrap-foot><table-wrap-foot><fn id="fn2"><label>a</label><p id="ntpara0020">V refers to the SARS-CoV-2 protein, and H refers to the human protein.</p></fn></table-wrap-foot><table-wrap-foot><fn id="fn3"><label>b</label><p id="ntpara0025">The number of predicted binding pockets by D3Pockets on the protein with the PPV greater than 200 Å<sup>3</sup>.</p></fn></table-wrap-foot><table-wrap-foot><fn id="fn4"><label>c</label><p id="ntpara0030">The orthosteric ligand binding sites assigned based on its sequence similarity (&gt;80%) to that of its homologous proteins.</p></fn></table-wrap-foot><table-wrap-foot><fn id="fn5"><label>d</label><p id="ntpara0035">Not available.</p></fn></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="sec2.2">
      <label>2.2</label>
      <title>Protein structure and 3D models</title>
      <p id="p0040">We performed literature survey and found 13 crystal structures of 6 proteins encoded by SARS-CoV-2 as well as 16 human proteins that may be the potential target proteins to cure COVID-19 with three-dimensional (3D) structures available from Protein Data Bank (PDB)<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref>. Therefore, their 3D structures were downloaded directly from PDB (<xref rid="tbl1" ref-type="table">Table 1</xref>).</p>
      <p id="p0045">Due to the missing residues of the viral crystal structures in comparison with the complete amino acid sequences, the 3D structures of total 19 viral proteins except ADP ribose phosphatase were reconstructed in two different ways, <italic>viz</italic>., homology modeling and <italic>de novo</italic> prediction. Among them, 16 proteins were modelled with SWISS-MODEL server (<ext-link ext-link-type="uri" xlink:href="https://swissmodel.expasy.org/" id="intref0010">https://swissmodel.expasy.org/</ext-link>; the Center for Molecular Life Sciences, Switzerland)<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> based on 22 homology structures in PDB, which are 2HSX, 3E9S, 5Y3E, 1Z1I, 2Z9J, 1YSY, 2AHM, 1UW7, 1QZ8, 5NFY, 6NUR, 6JYT, 2H85, 2XYR, 1YO4, 5X58, 5X5B, 5ZVM, 2MM4, 5X29, 2GIB, and 2OFZ (<xref rid="tbl1" ref-type="table">Table 1</xref>). Other three SARS-CoV-2 proteins have sequence similarity lower than 30% with the structures in PDB, therefore, we modelled their structures by Robetta (<ext-link ext-link-type="uri" xlink:href="http://robetta.bakerlab.org/" id="intref0015">http://robetta.bakerlab.org/</ext-link>; Baker lab, USA)<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> for <italic>de novo</italic> prediction, which are non-structural protein 2, non-structural protein 4, and non-structural protein 6 (<xref rid="tbl1" ref-type="table">Table 1</xref>). In addition, magnesium ions (Mg<sup>2+</sup>) are essential for the activity of the RNA-dependent RNA polymerase (RdRp). Therefore, we modelled two Mg<sup>2+</sup> from the superimposition of the HCV RdRp (PDB ID: <ext-link ext-link-type="uri" xlink:href="pdb:1NB6" id="intref0020">1NB6</ext-link>)<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> palm domain to SARS-CoV-2 RdRp palm domain.</p>
      <p id="p0050">As for the rest 6 human proteins without available crystal structures, 4 of them were modelled by SWISS-MODEL, and 2 were modelled by Robetta because of the poor sequence similarity (&lt;30%), which are transmembrane protease serine 2 (TMPRSS2) and caveolin-2. The biological functions of each protein are summarized in Supporting Information <xref rid="appsec1" ref-type="sec">Table S2</xref>.</p>
      <p id="p0055">In future we will keep our database updating regularly when new experimental and simulated structures of the potential target proteins related to COVID-19 are available. The update information could be found in the “updated” section in the D3Targets-2019-nCoV webserver.</p>
    </sec>
    <sec id="sec2.3">
      <label>2.3</label>
      <title>Detection of potential binding pockets</title>
      <p id="p0060">Since most of the drug binding pockets of SARS-CoV-2 proteins are unknown and very difficult to be obtained from experiments in a short time, a new method we reported recently, namely D3Pockets (<ext-link ext-link-type="uri" xlink:href="https://www.d3pharma.com/D3Pocket/index.php" id="intref0025">https://www.d3pharma.com/D3Pocket/index.php</ext-link>)<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref>, was applied to systematically predict all the potential binding pockets for each protein. Due to the irregular shape of the predicted binding pockets, we used cuboid pseudo-pocket volume (PPV) to characterize the size of protein pockets by Eq. <xref rid="fd1" ref-type="disp-formula">(1)</xref>. Once submitting a hydrogenated homology-modeled protein to the D3pockets webserver, the coordinates of predicted binding pockets in the protein could be predicted, among which pockets with the PPV greater than 200 Å<sup>3</sup> were selected for molecular docking in this study.<disp-formula id="fd1"><label>(1)</label><mml:math id="M1" altimg="si1.svg" alttext="Equation 1."><mml:mrow><mml:mspace width="0.25em"/><mml:mtext>PPV</mml:mtext><mml:mo linebreak="badbreak">=</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:msub><mml:mi>X</mml:mi><mml:mtext>max</mml:mtext></mml:msub><mml:mo linebreak="badbreak">−</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mtext>min</mml:mtext></mml:msub></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="badbreak">×</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mtext>max</mml:mtext></mml:msub><mml:mo linebreak="badbreak">−</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mtext>min</mml:mtext></mml:msub></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="goodbreak">×</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:msub><mml:mi>Z</mml:mi><mml:mtext>max</mml:mtext></mml:msub><mml:mo linebreak="badbreak">−</mml:mo><mml:msub><mml:mi>Z</mml:mi><mml:mtext>min</mml:mtext></mml:msub></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>where <inline-formula><mml:math id="M2" altimg="si2.svg"><mml:mrow><mml:msub><mml:mi>X</mml:mi><mml:mtext>max</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M3" altimg="si3.svg"><mml:mrow><mml:msub><mml:mi>X</mml:mi><mml:mtext>min</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> are the maximum and minimum values of the <italic>X</italic> coordinate in the pocket file, which was downloaded from the D3pockets server, respectively; <inline-formula><mml:math id="M4" altimg="si4.svg"><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mtext>max</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M5" altimg="si5.svg"><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mtext>min</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> are the maximum and minimum values of the <italic>Y</italic> coordinate in the pocket file; <inline-formula><mml:math id="M6" altimg="si6.svg"><mml:mrow><mml:msub><mml:mi>Z</mml:mi><mml:mtext>max</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M7" altimg="si7.svg"><mml:mrow><mml:msub><mml:mi>Z</mml:mi><mml:mtext>min</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> are the maximum and minimum values of the <italic>Z</italic> coordinate in the pocket file.</p>
      <p id="p0065">It is critical to choose appropriate docking box parameters for accurate prediction in molecular docking. Based on the coordinate file of predicted binding pockets by D3pockets, the center of the docking box is obtained by Eq. <xref rid="fd2" ref-type="disp-formula">(2)</xref>, and the size of the docking box is obtained by Eq. <xref rid="fd3" ref-type="disp-formula">(3)</xref> which extends 10 Å in each dimension of the cubic box.<disp-formula id="fd2"><label>(2)</label><mml:math id="M8" altimg="si8.svg" alttext="Equation 2."><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:mi>y</mml:mi><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:mi>z</mml:mi></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="badbreak">=</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>X</mml:mi><mml:mtext>max</mml:mtext></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mtext>min</mml:mtext></mml:msub></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:mfrac><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mtext>max</mml:mtext></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mtext>min</mml:mtext></mml:msub></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:mfrac><mml:mrow><mml:msub><mml:mi>Z</mml:mi><mml:mtext>max</mml:mtext></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mi>Z</mml:mi><mml:mtext>min</mml:mtext></mml:msub></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="fd3"><label>(3)</label><mml:math id="M9" altimg="si9.svg" alttext="Equation 3."><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:mi>b</mml:mi><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:mi>c</mml:mi></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="badbreak">=</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:msub><mml:mi>X</mml:mi><mml:mtext>max</mml:mtext></mml:msub><mml:mo linebreak="badbreak">−</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mtext>min</mml:mtext></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:mspace width="0.25em"/><mml:msub><mml:mi>Y</mml:mi><mml:mtext>max</mml:mtext></mml:msub><mml:mo linebreak="badbreak">−</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mtext>min</mml:mtext></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:msub><mml:mi>Z</mml:mi><mml:mtext>max</mml:mtext></mml:msub><mml:mo linebreak="badbreak">−</mml:mo><mml:msub><mml:mi>Z</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:mn>10</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>where <italic>x</italic>, <italic>y</italic> and <italic>z</italic> are the 3D coordinate centers of the docking box. And <italic>a</italic>, <italic>b</italic> and <italic>c</italic> are the widths of the docking box.</p>
    </sec>
    <sec id="sec2.4">
      <label>2.4</label>
      <title>Molecular dynamics simulation on SARS-CoV-2 M<sup>pro</sup></title>
      <p id="p0070">For exploring druggable conformations as many as possible for a potential drug target, molecular dynamics (MD) simulations were performed, with SARS-CoV-2 M<sup>pro</sup> as an example in this study, to sample more protein conformations by using our newly developed MD method, namely velocity-scaling optimized replica exchange molecular dynamics (vsREMD)<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref>. The details of the vsREMD method have been described in our previous study<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref>. Briefly, in the vsREMD, a set of replicas are simulated in explicit solvent environment at different temperatures, but exchange between neighboring replicas solely utilizes the sum of intra-protein interaction (<italic>P</italic><sub>pp</sub>) and protein–solvent interaction <inline-formula><mml:math id="M10" altimg="si10.svg"><mml:mo>(</mml:mo></mml:math></inline-formula><inline-formula><mml:math id="M11" altimg="si19.svg"><mml:msub><mml:mi mathvariant="italic">P</mml:mi><mml:mtext>pw</mml:mtext></mml:msub></mml:math></inline-formula><inline-formula><mml:math id="M12" altimg="si20.svg"><mml:mo>)</mml:mo></mml:math></inline-formula> as the criterion by Eq. <xref rid="fd4" ref-type="disp-formula">(4)</xref>:<disp-formula id="fd4"><label>(4)</label><mml:math id="M13" altimg="si11.svg" alttext="Equation 4."><mml:mrow><mml:mi>ω</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">↔</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="badbreak">=</mml:mo><mml:mtext>min</mml:mtext><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:mtext>exp</mml:mtext><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>Δ</mml:mi><mml:mi>β</mml:mi><mml:mi>Δ</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mtext>pp</mml:mtext></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mtext>pw</mml:mtext></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>where <italic>β</italic> is the inverse of temperature 1/<italic>k</italic><sub>B</sub><italic>T</italic>. To obtain the correct ensemble after exchange moves between replica 1 and replica 2, the vsREMD uses Eqs. <xref rid="fd5" ref-type="disp-formula">(5)</xref>, <xref rid="fd6" ref-type="disp-formula">(6)</xref> below to rescale uniformly the velocities of all particles.<disp-formula id="fd5"><label>(5)</label><mml:math id="M14" altimg="si12.svg" alttext="Equation 5."><mml:mrow><mml:msup><mml:mrow><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo>ˆ</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">→</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:mo linebreak="badbreak">=</mml:mo><mml:msup><mml:mi>v</mml:mi><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:msqrt><mml:mrow><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>E</mml:mi><mml:mtext>kin</mml:mtext><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:msubsup><mml:mo linebreak="badbreak">−</mml:mo><mml:mi>Δ</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mtext>ww</mml:mtext></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mi>E</mml:mi><mml:mtext>kin</mml:mtext><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:msqrt></mml:mrow></mml:math></disp-formula><disp-formula id="fd6"><label>(6)</label><mml:math id="M15" altimg="si13.svg" alttext="Equation 6."><mml:mrow><mml:msup><mml:mrow><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo>ˆ</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo linebreak="badbreak">→</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:mo linebreak="badbreak">=</mml:mo><mml:msup><mml:mi>v</mml:mi><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:msqrt><mml:mrow><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>E</mml:mi><mml:mtext>kin</mml:mtext><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:msubsup><mml:mo linebreak="badbreak">+</mml:mo><mml:mi>Δ</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mtext>ww</mml:mtext></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mi>E</mml:mi><mml:mtext>kin</mml:mtext><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:msqrt></mml:mrow></mml:math></disp-formula>where<inline-formula><mml:math id="M16" altimg="si14.svg"><mml:mrow><mml:mspace width="0.25em"/><mml:msup><mml:mi>v</mml:mi><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M17" altimg="si15.svg"><mml:mrow><mml:msubsup><mml:mi>E</mml:mi><mml:mtext>kin</mml:mtext><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> are the velocities and kinetic energies of replica 1 before exchange, respectively; <inline-formula><mml:math id="M18" altimg="si16.svg"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mtext>ww</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> is the intra-solvent interaction; <inline-formula><mml:math id="M19" altimg="si17.svg"><mml:mrow><mml:msup><mml:mrow><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo>ˆ</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">→</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> is the velocity of replica 1 after exchange. The same meaning for replica 2. </p>
      <p id="p0075">The initial structure of the SARS-CoV-2 M<sup>pro</sup> was obtained from homology modelling with 1Z1I as template. AMBER99SB∗-ILDNP<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> force field was used to model the protein. The simulation system was solvated in a cubic box of TIP3P water molecules with a 10.0 Å buffer along each dimension. To remove bad contacts formed during the system preparation, the simulation system was minimized using steepest descent algorithm. Then the system was heated to 300 from 0 K in 2 ns with a harmonic restraint (10 kcal/mol·Å<sup>−2</sup>) for the solute. The bonds connecting hydrogen atoms were constrained by the LINCS algorithm (an algorithm reseting bond's length; 1997)<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> and the time step was set to 2.0 fs. The long-range electrostatic interactions were treated by Particle mesh Ewald (PME, long-range electrostatic algorithms; 1993)<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> with the non-bonded cutoff of 12 Å. The vsREMD was run at 24 different temperatures from 300 to 450 K (300.0, 305.3, 310.8, 316.3, 321.9, 327.6, 333.5, 339.4, 345.4, 351.6, 357.8, 364.2, 370.7, 377.3, 384.0, 390.8, 397.8, 404.8, 412.0, 419.4, 426.8, 434.4, 442.1 and 450.0). Exchanges were attempted every 1000 steps. For each replica, the overall simulation time lasted for 50 ns.</p>
      <p id="p0080">After the vsREMD simulation, the representative conforamtions obtained from the trajectory were clustered and the correltation among different clusters and potential binding pockets were analyzed with D3Pockets<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref>.</p>
    </sec>
    <sec id="sec2.5">
      <label>2.5</label>
      <title>Molecular docking</title>
      <p id="p0085">Hydrogens were added to the protein structures by pdb2pqr<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref>. The format of protein structures was converted to pdbqt by using the script prepare_receptor4.py in MGLTools (version 1.5.6)<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref>. The pockets generated by D3Pockets are used to generate box and grid for docking. For the small molecule submitted for docking, the script prepare_ligand4.py in MGLTools (version 1.5.6) is used to convert its format of either mol2 or sdf to the format of pdbqt<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref>. All the docking process was performed with smina (<ext-link ext-link-type="uri" xlink:href="https://sourceforge.net/projects/smina/" id="intref0030">https://sourceforge.net/projects/smina/</ext-link>; open-source software, version Smina Sep 25 2019)<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref>, which is a fork of AutoDock Vina<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> with improved docking performance. The detailed formulas and parameters for the scoring function were introduced in Supporting Information <xref rid="appsec1" ref-type="sec">Table S3</xref>. The random seed was explicitly set to 0. The exhaustiveness of the global search was set to 8 (exhaustiveness), and 1 binding mode (num_modes) was generated and reported for each small molecule against each docking pocket.</p>
      <p id="p0090">For the docking against RdRp, the interaction between Mg<sup>2+</sup> and oxygen could not be handled by the default scoring function. Hence, a custom scoring function (0.3 atom_type_gaussian (t1 = Magnesium, t2 = OxygenXSAcceptor, o = 0, _w = 3, _c = 8)) is applied (<xref rid="appsec1" ref-type="sec">Table S3</xref>).</p>
    </sec>
    <sec id="sec2.6">
      <label>2.6</label>
      <title>Multi-protein and multi-pocket docking platform and webserver</title>
      <p id="p0095">All protein conformations and binding pockets were collated and used as the backend database of the D3Targets-2019-nCoV server. In the meantime, the molecular docking function was also embedded in the server. By submitting the compound file in format of mol2 or sdf <italic>via</italic> the website, the users can easily run a molecular docking job and download the result files including docking scores and the coordinates of the docked protein–ligand complexes from the D3Targets-2019-nCoV server. The workflow of D3Targets-2019-nCoV server is illustrated in <xref rid="fig1" ref-type="fig">Fig. 1</xref>.<fig id="fig1"><label>Figure 1</label><caption><p>The workflow of the D3Targets-2019-nCoV server for predicting drug targets and for multi-target and multi-site based virtual screening.</p></caption><alt-text id="alttext0020">Figure 1</alt-text><graphic xlink:href="gr1"/></fig></p>
    </sec>
  </sec>
  <sec id="sec3">
    <label>3</label>
    <title>Results and discussion</title>
    <sec id="sec3.1">
      <label>3.1</label>
      <title>Overview of target proteins in the D3Targets-2019-nCoV database</title>
      <p id="p0100">The information of the 42 proteins and 69 confromations collected in the D3Targets-2019-nCoV database were summarized in <xref rid="tbl1" ref-type="table">Table 1</xref>, including the protein name, state and conformation, number of pockets, orthosteric pockets, sequence similarity, PDB IDs of the downloaded structures or of the templates used for homology modeling, etc. For those proteins without PDB ID information, their structuers were modeled with Robetta. The pocket number on each conformation was also summarized in <xref rid="tbl1" ref-type="table">Table 1</xref>.</p>
    </sec>
    <sec id="sec3.2">
      <label>3.2</label>
      <title>D3Targets-2019-nCoV server</title>
      <p id="p0105">The D3Targets-2019-nCoV server was developed based on PHP, and hosted on a Linux server. The average running time for a docking job of a small molecule against all the 42 proteins and 557 binding sites is about an hour, but could be much longer if the molecule has large number of rotatable bonds. Upon a user uploading a molecular file, the D3Targets-2019-nCoV server will create a new job number and put it in queue immediately. The job status including “Computing”, “Waiting” and “Finished” will be shown on the result page. When the job is completed, the user can browse the result page to obtain docking scores for selected target proteins and can also download the docking results and the coordinate files related to ligand–protein interaction.</p>
    </sec>
    <sec id="sec3.3">
      <label>3.3</label>
      <title>Input and output</title>
      <p id="p0110">The graphical interface of the D3Targets-2019-nCoV webserver is shown in <xref rid="fig2" ref-type="fig">Fig. 2</xref>. The webserver supports small molecule files in several formats, such as sdf, mol2, mol, smiles, and pdb formats, which will be converted to mol2 format ultimately by Open Babel (version 2.4.0)<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> during the processing. Although 3D structures can be generated from the 2D coordinates and optimized under MMFF94 force field by RDKit (open-source cheminformatics software, version 2019.09.3, GitHub, Inc.), the chiral properties might be wrong in the conversion process. Therefore, we strongly recommend the users submitting 3D chemical structure in the format of mol2 or sdf, especially for the compounds with chiral centers.<fig id="fig2"><label>Figure 2</label><caption><p>Graphical interface for input (A) and output (B) of D3Targets-2019-nCoV.</p></caption><alt-text id="alttext0025">Figure 2</alt-text><graphic xlink:href="gr2"/></fig></p>
      <p id="p0115">Registration is encouraged to make the result only visible to the user, which is free of charge. After registration, the user can login to upload a small molecule. If a user is interested in one or some specific proteins, the target list is customized to be selected manually by the user, while the default is to run docking against all the proteins and sites. The output is presented in ascending order of ligand–protein docking score. The docking results could be downloaded from the webserver as an archive file.</p>
    </sec>
    <sec id="sec3.4">
      <label>3.4</label>
      <title>Potential allosteric binding pockets predicted with SARS-CoV-2 M<sup>pro</sup> as an example</title>
      <p id="p0120">D3Targets-2019-nCoV server has collected some and will continue to collect potential allosteric binding pockets to further improve its performance. As SARS-CoV-2 M<sup>pro</sup> is a promising target<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref>, we selected it as an example to demonstrate how we predict potential allosteric binding pockets. Based on the vsREMD simulation trajectories at 300 K, we applied D3Pockets to explore the dynamic properties of potential pockets in SARS-CoV-2 M<sup>pro</sup>. As shown in <xref rid="fig3" ref-type="fig">Fig. 3</xref>, there are grid points colored from blue to red that compose a pocket. The redder the grid points are, the more stable the sub-pocket regions throughout the MD trajectory. Therefore, for SARS-CoV-2 M<sup>pro</sup>, four relatively stable pockets are observed (<xref rid="fig3" ref-type="fig">Fig. 3</xref>). Pocket 1, where the intrinsic ligand binds to, has more stable points than Pockets 2, 3, and 4. Pocket 2, which is far from Pocket 1, has a positive volume correlation (0.60) with Pocket 1 (substrate binding site), suggesting that when Pocket 1 gets bigger, Pocket 2 gets bigger as well (<xref rid="fig4" ref-type="fig">Fig. 4</xref>A). Similarly, Pocket 3 also has a positive volume correlation (0.69) with Pocket 1 (<xref rid="fig4" ref-type="fig">Fig. 4</xref>B). There is no correlation between Pockets 1 and 4. It is well known that a pocket with strong correlation with the substrate binding pocket could be used as an allosteric site for drug discovery and development<xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref>. Therefore, Pockets 2 and 3 are two potential allosteric binding pockets, which were included in the D3Targets-2019-nCoV webserver. The cutoff of correlation coefficient to identify the allosteric binding pockets was set to 0.5 by default with the program D3Pockets<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref>.<fig id="fig3"><label>Figure 3</label><caption><p>Pocket stability of SARS-CoV-2 M<sup>pro</sup>. The protein and the binding pockets were prepared with PyMOL (The PyMOL molecular graphics system, version 2.4.2019, Schrodinger LLC.).</p></caption><alt-text id="alttext0030">Figure 3</alt-text><graphic xlink:href="gr3"/></fig><fig id="fig4"><label>Figure 4</label><caption><p>Pocket correlation of SARS-CoV-2 M<sup>pro</sup>.</p></caption><alt-text id="alttext0035">Figure 4</alt-text><graphic xlink:href="gr4"/></fig></p>
    </sec>
    <sec id="sec3.5">
      <label>3.5</label>
      <title>Case study</title>
      <p id="p0125">RdRp was recognized as a challenging protein for molecular docking, thus, we selected remdesivir as an example to test the reliability of D3Targets-2019-nCoV server. Remdesivir is a RdRp inhibitor and has been reported to be effective in inhibiting severe acute respiratory syndrome-related coronavirus (SARS-CoV) and SARS-CoV-2 <italic>in vitro</italic><xref rid="bib33" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="bib34" ref-type="bibr"><sup>34</sup></xref>. It should be noted that remdesivir is a prodrug, and the active form is the transformed nucleoside triphosphate (NTP, <xref rid="fig5" ref-type="fig">Fig. 5</xref>)<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref>. Therefore, NTP was submitted to D3Targets-2019-nCoV for the target prediction.<fig id="fig5"><label>Figure 5</label><caption><p>Remdesivir is converted to its pharmacologically active NTP in human cells.</p></caption><alt-text id="alttext0040">Figure 5</alt-text><graphic xlink:href="gr5"/></fig></p>
      <p id="p0130"><xref rid="tbl2" ref-type="table">Table 2</xref> presented the top 10 target proteins with high docking scores predicted by the server for NTP. The target protein of remdesivir, RdRp, has a score of −11.37 kcal/mol in Pocket 1, which ranks the 3rd among all protein pockets (42 proteins, 69 conformations and 557 binding pockets). However, it should be noted that docking score alone does not perform well in many cases according to our experience. We recommend the users to check the top 10 docking results carefully to identify potential target protein.<table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Top 10 proteins and their docking scores for NTP.</p></caption><alt-text id="alttext0055">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>No.</th><th>Protein</th><th>State/Conformation</th><th>Pocket code</th><th>Docking score</th></tr></thead><tbody><tr><td>1</td><td>Eukaryotic initiation factor 4A-I</td><td>/</td><td>2</td><td>−11.88</td></tr><tr><td>2</td><td>Dihydroorotate dehydrogenase</td><td>/</td><td>1</td><td>−11.54</td></tr><tr><td>3</td><td>RNA-dependent RNA polymerase</td><td>+Mg<sup>2+</sup></td><td>1</td><td>−11.37</td></tr><tr><td>4</td><td>cGMP-specific 3ʹ,5ʹ-cyclic phosphodiesterase</td><td>/</td><td>1</td><td>−10.35</td></tr><tr><td>5</td><td>Spike protein</td><td>Open</td><td>8</td><td>−10.28</td></tr><tr><td>6</td><td>ADP ribose phosphatase</td><td>Dimer</td><td>2</td><td>−10.15</td></tr><tr><td>7</td><td>Mitogen-activated protein kinase 10</td><td>/</td><td>1</td><td>−9.98</td></tr><tr><td>8</td><td>Uridylate-specific endoribonuclease</td><td>Monomer</td><td>1</td><td>−9.84</td></tr><tr><td>9</td><td>Guanine-<italic>N</italic>7 methyltransferase</td><td>/</td><td>1</td><td>−9.67</td></tr><tr><td>10</td><td>RAC-alpha serine/threonine-protein kinase</td><td>/</td><td>1</td><td>−9.40</td></tr></tbody></table></table-wrap></p>
      <p id="p0135">One superiority to use the docking method to predict the target is that the docked binding mode of the compound is useful for the mutagenesis validation and is also useful to ligand optimization. According to the binding mode, the residues, <italic>e.g</italic>., TRP-800, ASP-761, and CYS-622 of NTP were found to form hydrogen bonds with the RdRp (<xref rid="fig6" ref-type="fig">Fig. 6</xref>), and there is a strong electrostatic attraction between the phosphate group of NTP and two Mg<sup>2+</sup>. Thus, the residues and the cations are essential for the strong binding of NTP to RdRp. Comparing with the newly reported RdRp–remdesivir complex structure<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref>, 4 of the 6 key interaction residues, viz., D618, D623, D760 and D761, are included in our predicted key residues (<xref rid="fig6" ref-type="fig">Fig. 6</xref>). Therefore, the docking results by D3Targets-2019-nCoV webserver should be acceptable.<fig id="fig6"><label>Figure 6</label><caption><p>Binding mode of NTP to the RdRp from the docking simulation.</p></caption><alt-text id="alttext0045">Figure 6</alt-text><graphic xlink:href="gr6"/></fig></p>
      <p id="p0140">To further test the reliability of D3Targets-2019-nCoV server, we performed literature survery and found 5 more active compounds with experimental informaiton of target protein and bioactivity. Therefore, we performed target predition for the 5 active compounds to test whether the predicted targets are ranked in top 10 among the 42 potential target proteins. The predicted results were summarized in <xref rid="tbl3" ref-type="table">Table 3</xref>, in which all the experimentally reported targets were predicted to be among top 5, demonstrating that the results from D3Targets-2019-nCoV should be acceptable at least to the systems we tested.<table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Case studies of potential antiviral agents against the SARS-CoV-2.</p></caption><alt-text id="alttext0060">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th><break/>Antiviral agent</th><th>Target</th><th>Molecular structure</th><th>Antiviral activity (μmol/L)</th><th>Score</th><th>Rank</th><th>Ref.</th></tr></thead><tbody><tr><td>Remdesivir-active form</td><td>RdRp</td><td><inline-graphic xlink:href="fx2.gif"><alt-text id="alttext0065">Image 2</alt-text></inline-graphic></td><td>EC<sub>50</sub> = 0.77</td><td>−11.37</td><td>3/42</td><td><xref rid="bib34" ref-type="bibr">34</xref></td></tr><tr><td>Favipiravir-active form</td><td>RdRp</td><td><inline-graphic xlink:href="fx3.gif"><alt-text id="alttext0070">Image 3</alt-text></inline-graphic></td><td>EC<sub>50</sub> = 61.88</td><td>−10.74</td><td>2/42</td><td><xref rid="bib34" ref-type="bibr">34</xref>,<xref rid="bib37" ref-type="bibr">37</xref>,<xref rid="bib38" ref-type="bibr">38</xref></td></tr><tr><td>Ribavirin-active form</td><td>RdRp</td><td><inline-graphic xlink:href="fx4.gif"><alt-text id="alttext0075">Image 4</alt-text></inline-graphic></td><td>EC<sub>50</sub> = 109.50</td><td>−10.39</td><td>2/42</td><td><xref rid="bib34" ref-type="bibr">34</xref>,<xref rid="bib38" ref-type="bibr">38</xref>,<xref rid="bib39" ref-type="bibr">39</xref></td></tr><tr><td>Penciclovir-active form</td><td>RdRp</td><td><inline-graphic xlink:href="fx5.gif"><alt-text id="alttext0080">Image 5</alt-text></inline-graphic></td><td>EC<sub>50</sub> = 95.96</td><td>−8.82</td><td>5/42</td><td><xref rid="bib34" ref-type="bibr">34</xref>,<xref rid="bib40" ref-type="bibr">40</xref></td></tr><tr><td>N3 compound</td><td>3CLpro</td><td><inline-graphic xlink:href="fx6.gif"><alt-text id="alttext0085">Image 6</alt-text></inline-graphic></td><td>EC<sub>50</sub> = 16.77</td><td>−9.45</td><td>4/42</td><td><xref rid="bib41" ref-type="bibr">41</xref></td></tr><tr><td>Teriflunomide</td><td>DHODH</td><td><inline-graphic xlink:href="fx7.gif"><alt-text id="alttext0090">Image 7</alt-text></inline-graphic></td><td>IC<sub>50</sub> = 0.31</td><td>−9.26</td><td>2/42</td><td><xref rid="bib42" ref-type="bibr">42</xref></td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="sec3.6">
      <label>3.6</label>
      <title>Discussion</title>
      <p id="p0145">We have presented the user-friendly D3Targets-2019-nCoV webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19. Compared with existing reverse docking platforms<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref>, the D3Targets-2019-nCoV webserver is specifically focused on COVID-19, including not only the experimental structures and homology models, but also the conformations with potential allosteric binding sites predicted by enhanced sampling method (vsREMD)<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> and D3Pockets<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref>, respectively. The abundant conformations and binding pockets make the webserver much possible to successfully predict target proteins and to discover hit compounds. It is also important to notice that other reverse docking platforms should be tried as the true targets of an active compound may not be included in D3Targets-2019-nCoV due to the unknown pathogenic mechanisms of COVID-19. Because the protein conformation obtained by homology modelling may not be the most stable conformation, and some docking models still need further optimization, for example, the positions of two Mg<sup>2+</sup> on the RdRp, the workflow of D3Targets-2019-nCoV needs to be further improved.</p>
      <p id="p0150">In order to keep the D3Targets-2019-nCoV server fresh and active, we will continue to update the webserver in the future. To make better use of the docking platform, some applications are listed as follows: (1) target prediction of multi-target drugs; (2) target prediction of old drugs and novel active compounds; (3) virtual screening of drugs for specified targets; (4) prediction of binding modes of drugs to known targets, and (5) users can download protein models for free from the webserver for molecular dynamics simulation, molecular docking or structure–activity relationship studies, etc. In particular, predicting target based only on the highest docking score may not be reliable. Therefore, we strongly recommend that the users take into account the docked binding mode and docking scores together with protein function. The D3Targets-2019-nCoV webserver will keep regularly update when the new structures of potential target proteins related to COVID-19 are available and meet one of the 4 criteria, viz., natural mutant, RMSDs of the overall structure or ligand binding pockets or any key residue in the pockets ≥2 Å to any structures in the webserver.</p>
    </sec>
  </sec>
  <sec id="sec4">
    <label>4</label>
    <title>Conclusions</title>
    <p id="p0155">SARS-CoV-2 has caused more than 2,800 deaths as of 29 February 2020 worldwide. Although there is no effective drug approved, many clinical trials are incoming or ongoing in China. Moreover, many groups are working on the cytopathic effect assay for discovering active compound. In many cases, the target protein of the discovered active compounds might be unknown. Therefore, identifying potential drug targets will be of great importance. Here, we developed a webserver for predicting potential target protein for active compounds and for virtual screening against multi-target and multi-pockets. The webserver database currently has 42 proteins (20 viral proteins and 22 human proteins related to virus infection, replication and release) with 69 conformations collected by means of downloading directly from PDB, homology and <italic>de novo</italic> modeling, and the MD simulation. With the program D3Pockets, 557 potential ligand binding pockets were successfully predicted and used for molecular docking by the server. Each submitted compound will be docked to all the binding pockets by smina, and the docking results will be presented in ascending order of docking score. Tests with 6 active compounds/drugs with experimental reported target proteins and bioactivity data demonstrated the potential usefulness of the D3Targets-2019-nCoV server. The webser is accessible <italic>via</italic> internet free of charge at <ext-link ext-link-type="uri" xlink:href="https://www.d3pharma.com/D3Targets-2019-nCoV/index.php" id="intref0035">https://www.d3pharma.com/D3Targets-2019-nCoV/index.php</ext-link>.</p>
  </sec>
  <sec id="sec5">
    <title>Acknowledgments</title>
    <p id="p0170">This work was supported by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100013290</institution-id><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source> (2017YFB0202601 and 2016YFA0502301).</p>
  </sec>
  <sec id="sec6">
    <title>Author contributions</title>
    <p id="p0160">Weiliang Zhu and Zhijian Xu conceived and designed the study. Yulong Shi and Xinben Zhang wrote the script code for the webserver. Yulong Shi, Kaijie Mu, Cheng Peng, Zhengdan Zhu, Xiaoyu Wang and Yanqing Yang collected the data, performed homology modelling and molecular dynamics simulation, and developed docking models. Yulong Shi and Cheng Peng performed the data analysis. Weiliang Zhu, Zhijian Xu, Yulong Shi and Cheng Peng wrote the paper.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflicts of interest</title>
    <p id="p0165">The authors have no conflicts of interest to declare.</p>
  </sec>
</body>
<back>
  <ref-list id="cebib0010">
    <title>References</title>
    <ref id="bib1">
      <label>1</label>
      <element-citation publication-type="journal" id="sref1">
        <person-group person-group-type="author">
          <name>
            <surname>Zhu</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title>
        <source>N Engl J Med</source>
        <volume>382</volume>
        <year>2020</year>
        <fpage>727</fpage>
        <lpage>733</lpage>
        <pub-id pub-id-type="pmid">31978945</pub-id>
      </element-citation>
    </ref>
    <ref id="bib2">
      <label>2</label>
      <element-citation publication-type="journal" id="sref2">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>X.L.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X.G.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>W.</given-names>
          </name>
        </person-group>
        <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>
        <source>Nature</source>
        <volume>579</volume>
        <year>2020</year>
        <fpage>270</fpage>
        <lpage>273</lpage>
        <pub-id pub-id-type="pmid">32015507</pub-id>
      </element-citation>
    </ref>
    <ref id="bib3">
      <label>3</label>
      <element-citation publication-type="journal" id="sref3">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y.M.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>Z.G.</given-names>
          </name>
        </person-group>
        <article-title>A new coronavirus associated with human respiratory disease in China</article-title>
        <source>Nature</source>
        <volume>579</volume>
        <year>2020</year>
        <fpage>265</fpage>
        <lpage>269</lpage>
        <pub-id pub-id-type="pmid">32015508</pub-id>
      </element-citation>
    </ref>
    <ref id="bib4">
      <label>4</label>
      <element-citation publication-type="journal" id="sref4">
        <person-group person-group-type="author">
          <name>
            <surname>Holshue</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>DeBolt</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Lindquist</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Lofy</surname>
            <given-names>K.H.</given-names>
          </name>
          <name>
            <surname>Wiesman</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Bruce</surname>
            <given-names>H.</given-names>
          </name>
        </person-group>
        <article-title>First case of 2019 novel coronavirus in the United States</article-title>
        <source>N Engl J Med</source>
        <volume>382</volume>
        <year>2020</year>
        <fpage>929</fpage>
        <lpage>936</lpage>
        <pub-id pub-id-type="pmid">32004427</pub-id>
      </element-citation>
    </ref>
    <ref id="bib5">
      <label>5</label>
      <element-citation publication-type="journal" id="sref5">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X.J.</given-names>
          </name>
        </person-group>
        <article-title>Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines</article-title>
        <source>J Genet Genomics</source>
        <volume>47</volume>
        <year>2020</year>
        <fpage>119</fpage>
        <lpage>121</lpage>
        <pub-id pub-id-type="pmid">32173287</pub-id>
      </element-citation>
    </ref>
    <ref id="bib6">
      <label>6</label>
      <element-citation publication-type="journal" id="sref6">
        <person-group person-group-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Peng</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Mu</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X.</given-names>
          </name>
        </person-group>
        <article-title>Nelfinavir was predicted to be a potential inhibitor of 2019-nCoV main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation</article-title>
        <source>bioRxiv</source>
        <year>2020</year>
        <comment>Available from:</comment>
        <pub-id pub-id-type="doi">10.1101/2020.01.27.921627</pub-id>
      </element-citation>
    </ref>
    <ref id="bib7">
      <label>7</label>
      <element-citation publication-type="journal" id="sref7">
        <person-group person-group-type="author">
          <name>
            <surname>Beck</surname>
            <given-names>B.R.</given-names>
          </name>
          <name>
            <surname>Shin</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Choi</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Kang</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug–target interaction deep learning model</article-title>
        <source>bioRxiv</source>
        <year>2020</year>
        <comment>Available from:</comment>
        <pub-id pub-id-type="doi">10.1101/2020.01.31.929547</pub-id>
      </element-citation>
    </ref>
    <ref id="bib8">
      <label>8</label>
      <element-citation publication-type="journal" id="sref8">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <article-title>Therapeutic drugs targeting 2019-nCoV main protease by high-throughput screening</article-title>
        <source>bioRxiv</source>
        <year>2020</year>
        <comment>Available from:</comment>
        <pub-id pub-id-type="doi">10.1101/2020.01.28.922922</pub-id>
      </element-citation>
    </ref>
    <ref id="bib9">
      <label>9</label>
      <element-citation publication-type="journal" id="sref9">
        <person-group person-group-type="author">
          <name>
            <surname>Anh-Tien</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Francesco</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Michael</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Fuqiang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Artem</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds</article-title>
        <source>Mol Inf</source>
        <volume>39</volume>
        <year>2020</year>
        <fpage>2000028</fpage>
      </element-citation>
    </ref>
    <ref id="bib10">
      <label>10</label>
      <element-citation publication-type="journal" id="sref10">
        <person-group person-group-type="author">
          <name>
            <surname>Alessandro</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>Virtual screening of an FDA approved drugs database on two COVID-19 coronavirus proteins</article-title>
        <source>ChemRxiv</source>
        <year>2020</year>
        <comment>Available from:</comment>
        <pub-id pub-id-type="doi">10.26434/chemrxiv.11847381.v1</pub-id>
      </element-citation>
    </ref>
    <ref id="bib11">
      <label>11</label>
      <element-citation publication-type="journal" id="sref11">
        <person-group person-group-type="author">
          <name>
            <surname>Yu Wai</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Chin-Pang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Kwok-Yin</surname>
            <given-names>W.</given-names>
          </name>
        </person-group>
        <article-title>Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates</article-title>
        <source>ChemRxiv</source>
        <year>2020</year>
        <comment>Available from:</comment>
        <pub-id pub-id-type="doi">10.26434/chemrxiv.11831103.v2</pub-id>
      </element-citation>
    </ref>
    <ref id="bib12">
      <label>12</label>
      <element-citation publication-type="journal" id="sref12">
        <person-group person-group-type="author">
          <name>
            <surname>Nguyen</surname>
            <given-names>D.D.</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Wei</surname>
            <given-names>G.W.</given-names>
          </name>
        </person-group>
        <article-title>Potentially highly potent drugs for 2019-nCoV</article-title>
        <source>bioRxiv</source>
        <year>2020</year>
        <comment>Available from:</comment>
        <pub-id pub-id-type="doi">10.1101/2020.02.05.936013</pub-id>
      </element-citation>
    </ref>
    <ref id="bib13">
      <label>13</label>
      <element-citation publication-type="journal" id="sref13">
        <person-group person-group-type="author">
          <name>
            <surname>Cui</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Ji</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>Possible inhibitors of ACE2, the receptor of 2019-nCoV</article-title>
        <source>Preprints</source>
        <year>2020</year>
        <comment>Available from:</comment>
        <pub-id pub-id-type="doi">10.20944/preprints202002.0047.v1</pub-id>
      </element-citation>
    </ref>
    <ref id="bib14">
      <label>14</label>
      <element-citation publication-type="journal" id="sref14">
        <person-group person-group-type="author">
          <name>
            <surname>Rimanshee</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Amit</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Vishal</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Mukesh</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs</article-title>
        <source>ChemRxiv</source>
        <year>2020</year>
        <comment>Available from:</comment>
        <pub-id pub-id-type="doi">10.26434/chemrxiv.11860011.v2</pub-id>
      </element-citation>
    </ref>
    <ref id="bib15">
      <label>15</label>
      <element-citation publication-type="journal" id="sref15">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>Furin, a potential therapeutic target for COVID-19</article-title>
        <source>ChinaXiv</source>
        <year>2020</year>
        <comment>Available from:</comment>
        <pub-id pub-id-type="doi">10.12074/202002.00062</pub-id>
      </element-citation>
    </ref>
    <ref id="bib16">
      <label>16</label>
      <element-citation publication-type="journal" id="sref16">
        <person-group person-group-type="author">
          <name>
            <surname>Burley</surname>
            <given-names>S.K.</given-names>
          </name>
          <name>
            <surname>Berman</surname>
            <given-names>H.M.</given-names>
          </name>
          <name>
            <surname>Bhikadiya</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Bi</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Di Costanzo</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy</article-title>
        <source>Nucleic Acids Res</source>
        <volume>47</volume>
        <year>2018</year>
        <fpage>D464</fpage>
        <lpage>D474</lpage>
      </element-citation>
    </ref>
    <ref id="bib17">
      <label>17</label>
      <element-citation publication-type="journal" id="sref17">
        <person-group person-group-type="author">
          <name>
            <surname>Waterhouse</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Bertoni</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Bienert</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Studer</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Tauriello</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Gumienny</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>SWISS-MODEL: homology modelling of protein structures and complexes</article-title>
        <source>Nucleic Acids Res</source>
        <volume>46</volume>
        <year>2018</year>
        <fpage>W296</fpage>
        <lpage>W303</lpage>
        <pub-id pub-id-type="pmid">29788355</pub-id>
      </element-citation>
    </ref>
    <ref id="bib18">
      <label>18</label>
      <element-citation publication-type="journal" id="sref18">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>D.E.</given-names>
          </name>
          <name>
            <surname>Chivian</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Baker</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>Protein structure prediction and analysis using the Robetta server</article-title>
        <source>Nucleic Acids Res</source>
        <volume>32</volume>
        <year>2004</year>
        <fpage>W526</fpage>
        <lpage>W531</lpage>
        <pub-id pub-id-type="pmid">15215442</pub-id>
      </element-citation>
    </ref>
    <ref id="bib19">
      <label>19</label>
      <element-citation publication-type="journal" id="sref19">
        <person-group person-group-type="author">
          <name>
            <surname>O'Farrell</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Trowbridge</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Rowlands</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Jager</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and <italic>de-novo</italic> initiation</article-title>
        <source>J Mol Biol</source>
        <volume>326</volume>
        <year>2003</year>
        <fpage>1025</fpage>
        <lpage>1035</lpage>
        <pub-id pub-id-type="pmid">12589751</pub-id>
      </element-citation>
    </ref>
    <ref id="bib20">
      <label>20</label>
      <element-citation publication-type="journal" id="sref20">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Peng</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>D3Pockets: a method and web server for systematic analysis of protein pocket dynamics</article-title>
        <source>J Chem Inf Model</source>
        <volume>59</volume>
        <year>2019</year>
        <fpage>3353</fpage>
        <lpage>3358</lpage>
        <pub-id pub-id-type="pmid">31265282</pub-id>
      </element-citation>
    </ref>
    <ref id="bib21">
      <label>21</label>
      <element-citation publication-type="journal" id="sref21">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Peng</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Exploring conformational change of adenylate kinase by replica exchange molecular dynamic simulation</article-title>
        <source>Biophys J</source>
        <volume>118</volume>
        <year>2020</year>
        <fpage>1009</fpage>
        <lpage>1018</lpage>
        <pub-id pub-id-type="pmid">31995738</pub-id>
      </element-citation>
    </ref>
    <ref id="bib22">
      <label>22</label>
      <element-citation publication-type="journal" id="sref22">
        <person-group person-group-type="author">
          <name>
            <surname>Aliev</surname>
            <given-names>A.E.</given-names>
          </name>
          <name>
            <surname>Kulke</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Khaneja</surname>
            <given-names>H.S.</given-names>
          </name>
          <name>
            <surname>Chudasama</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Sheppard</surname>
            <given-names>T.D.</given-names>
          </name>
          <name>
            <surname>Lanigan</surname>
            <given-names>R.M.</given-names>
          </name>
        </person-group>
        <article-title>Motional timescale predictions by molecular dynamics simulations: case study using proline and hydroxyproline sidechain dynamics</article-title>
        <source>Proteins</source>
        <volume>82</volume>
        <year>2014</year>
        <fpage>195</fpage>
        <lpage>215</lpage>
        <pub-id pub-id-type="pmid">23818175</pub-id>
      </element-citation>
    </ref>
    <ref id="bib23">
      <label>23</label>
      <element-citation publication-type="journal" id="sref23">
        <person-group person-group-type="author">
          <name>
            <surname>Hess</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Bekker</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Berendsen</surname>
            <given-names>H.J.C.</given-names>
          </name>
          <name>
            <surname>Fraaije</surname>
            <given-names>J.G.E.M.</given-names>
          </name>
        </person-group>
        <article-title>LINCS: a linear constraint solver for molecular simulations</article-title>
        <source>J Comput Chem</source>
        <volume>18</volume>
        <year>1997</year>
        <fpage>1463</fpage>
        <lpage>1472</lpage>
      </element-citation>
    </ref>
    <ref id="bib24">
      <label>24</label>
      <element-citation publication-type="journal" id="sref24">
        <person-group person-group-type="author">
          <name>
            <surname>Darden</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>York</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Pedersen</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>Particle mesh Ewald: an <italic>N</italic>⋅log (<italic>N</italic>) method for Ewald sums in large systems</article-title>
        <source>J Chem Phys</source>
        <volume>98</volume>
        <year>1993</year>
        <fpage>10089</fpage>
      </element-citation>
    </ref>
    <ref id="bib25">
      <label>25</label>
      <element-citation publication-type="journal" id="sref25">
        <person-group person-group-type="author">
          <name>
            <surname>Dolinsky</surname>
            <given-names>T.J.</given-names>
          </name>
          <name>
            <surname>Nielsen</surname>
            <given-names>J.E.</given-names>
          </name>
          <name>
            <surname>McCammon</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Baker</surname>
            <given-names>N.A.</given-names>
          </name>
        </person-group>
        <article-title>PDB2PQR: an automated pipeline for the setup of Poisson–Boltzmann electrostatics calculations</article-title>
        <source>Nucleic Acids Res</source>
        <volume>32</volume>
        <year>2004</year>
        <fpage>W665</fpage>
        <lpage>W667</lpage>
        <pub-id pub-id-type="pmid">15215472</pub-id>
      </element-citation>
    </ref>
    <ref id="bib26">
      <label>26</label>
      <element-citation publication-type="journal" id="sref26">
        <person-group person-group-type="author">
          <name>
            <surname>Morris</surname>
            <given-names>G.M.</given-names>
          </name>
          <name>
            <surname>Huey</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Lindstrom</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Sanner</surname>
            <given-names>M.F.</given-names>
          </name>
          <name>
            <surname>Belew</surname>
            <given-names>R.K.</given-names>
          </name>
          <name>
            <surname>Goodsell</surname>
            <given-names>D.S.</given-names>
          </name>
        </person-group>
        <article-title>AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility</article-title>
        <source>J Comput Chem</source>
        <volume>30</volume>
        <year>2009</year>
        <fpage>2785</fpage>
        <lpage>2791</lpage>
        <pub-id pub-id-type="pmid">19399780</pub-id>
      </element-citation>
    </ref>
    <ref id="bib27">
      <label>27</label>
      <element-citation publication-type="journal" id="sref27">
        <person-group person-group-type="author">
          <name>
            <surname>Koes</surname>
            <given-names>D.R.</given-names>
          </name>
          <name>
            <surname>Baumgartner</surname>
            <given-names>M.P.</given-names>
          </name>
          <name>
            <surname>Camacho</surname>
            <given-names>C.J.</given-names>
          </name>
        </person-group>
        <article-title>Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise</article-title>
        <source>J Chem Inf Model</source>
        <volume>53</volume>
        <year>2013</year>
        <fpage>1893</fpage>
        <lpage>1904</lpage>
        <pub-id pub-id-type="pmid">23379370</pub-id>
      </element-citation>
    </ref>
    <ref id="bib28">
      <label>28</label>
      <element-citation publication-type="journal" id="sref28">
        <person-group person-group-type="author">
          <name>
            <surname>Trott</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Olson</surname>
            <given-names>A.J.</given-names>
          </name>
        </person-group>
        <article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title>
        <source>J Comput Chem</source>
        <volume>31</volume>
        <year>2010</year>
        <fpage>455</fpage>
        <lpage>461</lpage>
        <pub-id pub-id-type="pmid">19499576</pub-id>
      </element-citation>
    </ref>
    <ref id="bib29">
      <label>29</label>
      <element-citation publication-type="journal" id="sref29">
        <person-group person-group-type="author">
          <name>
            <surname>O'Boyle</surname>
            <given-names>N.M.</given-names>
          </name>
          <name>
            <surname>Banck</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>James</surname>
            <given-names>C.A.</given-names>
          </name>
          <name>
            <surname>Morley</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Vandermeersch</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Hutchison</surname>
            <given-names>G.R.</given-names>
          </name>
        </person-group>
        <article-title>Open Babel: an open chemical toolbox</article-title>
        <source>J Cheminf</source>
        <volume>3</volume>
        <year>2011</year>
        <fpage>33</fpage>
      </element-citation>
    </ref>
    <ref id="bib30">
      <label>30</label>
      <element-citation publication-type="journal" id="sref30">
        <person-group person-group-type="author">
          <name>
            <surname>Suel</surname>
            <given-names>G.M.</given-names>
          </name>
          <name>
            <surname>Lockless</surname>
            <given-names>S.W.</given-names>
          </name>
          <name>
            <surname>Wall</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Ranganathan</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>Evolutionarily conserved networks of residues mediate allosteric communication in proteins</article-title>
        <source>Nat Struct Biol</source>
        <volume>10</volume>
        <year>2003</year>
        <fpage>59</fpage>
        <lpage>69</lpage>
        <pub-id pub-id-type="pmid">12483203</pub-id>
      </element-citation>
    </ref>
    <ref id="bib31">
      <label>31</label>
      <element-citation publication-type="journal" id="sref31">
        <person-group person-group-type="author">
          <name>
            <surname>Gerek</surname>
            <given-names>Z.N.</given-names>
          </name>
          <name>
            <surname>Ozkan</surname>
            <given-names>S.B.</given-names>
          </name>
        </person-group>
        <article-title>Change in allosteric network affects binding affinities of PDZ domains: analysis through perturbation response scanning</article-title>
        <source>PLoS Comput Biol</source>
        <volume>7</volume>
        <year>2011</year>
        <object-id pub-id-type="publisher-id">e1002154</object-id>
      </element-citation>
    </ref>
    <ref id="bib32">
      <label>32</label>
      <element-citation publication-type="journal" id="sref32">
        <person-group person-group-type="author">
          <name>
            <surname>Ma</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Meng</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Lai</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>Motions of allosteric and orthosteric ligand-binding sites in proteins are highly correlated</article-title>
        <source>J Chem Inf Model</source>
        <volume>56</volume>
        <year>2016</year>
        <fpage>1725</fpage>
        <lpage>1733</lpage>
        <pub-id pub-id-type="pmid">27580047</pub-id>
      </element-citation>
    </ref>
    <ref id="bib33">
      <label>33</label>
      <element-citation publication-type="journal" id="sref33">
        <person-group person-group-type="author">
          <name>
            <surname>Agostini</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>Andres</surname>
            <given-names>E.L.</given-names>
          </name>
          <name>
            <surname>Sims</surname>
            <given-names>A.C.</given-names>
          </name>
          <name>
            <surname>Graham</surname>
            <given-names>R.L.</given-names>
          </name>
          <name>
            <surname>Sheahan</surname>
            <given-names>T.P.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>X.</given-names>
          </name>
        </person-group>
        <article-title>Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease</article-title>
        <source>mBio</source>
        <volume>9</volume>
        <year>2018</year>
        <comment>e00221-18</comment>
      </element-citation>
    </ref>
    <ref id="bib34">
      <label>34</label>
      <element-citation publication-type="journal" id="sref34">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) <italic>in vitro</italic></article-title>
        <source>Cell Res</source>
        <volume>30</volume>
        <year>2020</year>
        <fpage>269</fpage>
        <lpage>271</lpage>
        <pub-id pub-id-type="pmid">32020029</pub-id>
      </element-citation>
    </ref>
    <ref id="bib35">
      <label>35</label>
      <element-citation publication-type="journal" id="sref35">
        <person-group person-group-type="author">
          <name>
            <surname>Warren</surname>
            <given-names>T.K.</given-names>
          </name>
          <name>
            <surname>Jordan</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Lo</surname>
            <given-names>M.K.</given-names>
          </name>
          <name>
            <surname>Ray</surname>
            <given-names>A.S.</given-names>
          </name>
          <name>
            <surname>Mackman</surname>
            <given-names>R.L.</given-names>
          </name>
          <name>
            <surname>Soloveva</surname>
            <given-names>V.</given-names>
          </name>
        </person-group>
        <article-title>Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys</article-title>
        <source>Nature</source>
        <volume>531</volume>
        <year>2016</year>
        <fpage>381</fpage>
        <lpage>385</lpage>
        <pub-id pub-id-type="pmid">26934220</pub-id>
      </element-citation>
    </ref>
    <ref id="bib36">
      <label>36</label>
      <element-citation publication-type="journal" id="sref36">
        <person-group person-group-type="author">
          <name>
            <surname>Gao</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target</article-title>
        <source>bioRxiv</source>
        <year>2020</year>
        <comment>Available from:</comment>
        <pub-id pub-id-type="doi">10.1101/2020.03.16.993386</pub-id>
      </element-citation>
    </ref>
    <ref id="bib37">
      <label>37</label>
      <element-citation publication-type="journal" id="sref37">
        <person-group person-group-type="author">
          <name>
            <surname>Furuta</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Komeno</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Nakamura</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase</article-title>
        <source>Proc Jpn Acad Ser B Phys Biol Sci</source>
        <volume>93</volume>
        <year>2017</year>
        <fpage>449</fpage>
        <lpage>463</lpage>
      </element-citation>
    </ref>
    <ref id="bib38">
      <label>38</label>
      <element-citation publication-type="journal" id="sref38">
        <person-group person-group-type="author">
          <name>
            <surname>Tchesnokov</surname>
            <given-names>E.P.</given-names>
          </name>
          <name>
            <surname>Feng</surname>
            <given-names>J.Y.</given-names>
          </name>
          <name>
            <surname>Porter</surname>
            <given-names>D.P.</given-names>
          </name>
          <name>
            <surname>Gotte</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir</article-title>
        <source>Viruses</source>
        <year>2019</year>
        <fpage>11</fpage>
      </element-citation>
    </ref>
    <ref id="bib39">
      <label>39</label>
      <element-citation publication-type="journal" id="sref39">
        <person-group person-group-type="author">
          <name>
            <surname>Guo</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>Strategies for ribavirin prodrugs and delivery systems for reducing the side-effect hemolysis and enhancing their therapeutic effect</article-title>
        <source>J Contr Release</source>
        <volume>209</volume>
        <year>2015</year>
        <fpage>27</fpage>
        <lpage>36</lpage>
      </element-citation>
    </ref>
    <ref id="bib40">
      <label>40</label>
      <element-citation publication-type="journal" id="sref40">
        <person-group person-group-type="author">
          <name>
            <surname>Earnshaw</surname>
            <given-names>D.L.</given-names>
          </name>
          <name>
            <surname>Bacon</surname>
            <given-names>T.H.</given-names>
          </name>
          <name>
            <surname>Darlison</surname>
            <given-names>S.J.</given-names>
          </name>
          <name>
            <surname>Edmonds</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Perkins</surname>
            <given-names>R.M.</given-names>
          </name>
          <name>
            <surname>Vere Hodge</surname>
            <given-names>R.A.</given-names>
          </name>
        </person-group>
        <article-title>Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus</article-title>
        <source>Antimicrob Agents Chemother</source>
        <volume>36</volume>
        <year>1992</year>
        <fpage>2747</fpage>
        <lpage>2757</lpage>
        <pub-id pub-id-type="pmid">1336346</pub-id>
      </element-citation>
    </ref>
    <ref id="bib41">
      <label>41</label>
      <element-citation publication-type="journal" id="sref41">
        <person-group person-group-type="author">
          <name>
            <surname>Jin</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Du</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Deng</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>Structure of Mpro from COVID-19 virus and discovery of its inhibitors</article-title>
        <source>bioRxiv</source>
        <year>2020</year>
        <comment>Available from:</comment>
        <pub-id pub-id-type="doi">10.1101/2020.02.26.964882</pub-id>
      </element-citation>
    </ref>
    <ref id="bib42">
      <label>42</label>
      <element-citation publication-type="journal" id="sref42">
        <person-group person-group-type="author">
          <name>
            <surname>Xiong</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2</article-title>
        <source>bioRxiv</source>
        <year>2020</year>
        <comment>Available from:</comment>
        <pub-id pub-id-type="doi">10.1101/2020.03.11.983056</pub-id>
      </element-citation>
    </ref>
    <ref id="bib43">
      <label>43</label>
      <element-citation publication-type="journal" id="sref43">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Kang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>TarFisDock: a web server for identifying drug targets with docking approach</article-title>
        <source>Nucleic Acids Res</source>
        <volume>34</volume>
        <year>2006</year>
        <fpage>W219</fpage>
        <lpage>W224</lpage>
        <pub-id pub-id-type="pmid">16844997</pub-id>
      </element-citation>
    </ref>
    <ref id="bib44">
      <label>44</label>
      <element-citation publication-type="journal" id="sref44">
        <person-group person-group-type="author">
          <name>
            <surname>Kharkar</surname>
            <given-names>P.S.</given-names>
          </name>
          <name>
            <surname>Warrier</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Gaud</surname>
            <given-names>R.S.</given-names>
          </name>
        </person-group>
        <article-title>Reverse docking: a powerful tool for drug repositioning and drug rescue</article-title>
        <source>Future Med Chem</source>
        <volume>6</volume>
        <year>2014</year>
        <fpage>333</fpage>
        <lpage>342</lpage>
        <pub-id pub-id-type="pmid">24575968</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="appsec1" sec-type="supplementary-material">
    <label>Appendix A</label>
    <title>Supplementary data</title>
    <p id="p0175">The following is the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1"><caption><title>Multimedia component 1</title></caption><media xlink:href="mmc1.pdf"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p>
  </sec>
  <fn-group>
    <fn id="d32e1829">
      <p id="ntpara0010">Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.</p>
    </fn>
    <fn id="appsec2" fn-type="supplementary-material">
      <label>Appendix A</label>
      <p id="p0180">Supporting data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.apsb.2020.04.006" id="intref0040">https://doi.org/10.1016/j.apsb.2020.04.006</ext-link>.</p>
    </fn>
  </fn-group>
</back>
